Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott will gain Piramal's branded generics unit, expected to generate more than $500 million in sales in 2011.
You may also be interested in...
Deals Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?
Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.
Abbott Ups Emerging Markets Ante With Zydus Deal, Established Products Unit
Abbott licenses 24 drugs from Zydos and forms an Established Products Division focused on emerging markets.
Piramal Close To Buying Local Critical Care Brands With An Eye On Global Markets
MUMBAI - Indian drug maker Piramal Healthcare's ambition to grow into a world player in hospital and critical care products is set to cross another milestone with the likely acquisition of a few brands in the anesthesia segment from an unlisted Indian pharmaceutical company